Navigation Links
EPIX Pharmaceuticals Announces Statistically Significant Results in,Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug,Candidate

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) announced today positive cognitive function results from its Phase 1b multiple ascending dose clinical trial of PRX-07034, the company's internally-discovered, novel 5-HT6 antagonist being developed for obesity, Alzheimer's disease and cognitive impairment associated with schizophrenia.

The randomized, double-blind, placebo-controlled Phase 1b, multiple ascending dose clinical trial was designed to study the safety, tolerability, pharmacokinetics, and pharmacodynamics of PRX-07034 administered orally once-daily for 28 days in a population of obese, but otherwise healthy, adults (average weight 100kg or 220 pounds). The 33-person trial, which was conducted in an in-patient setting, included measures to assess potential effects on cognitive function and obesity. Highlights from the study include: -0-

-- Primary endpoint: safety and tolerability.


    -- PRX-07034 was well tolerated up to 600 mg once per day. No dose

       limiting toxicity was identified, and no serious adverse events

       were reported. There were no withdrawals due to adverse events.


    -- PRX-07034 demonstrated predictable pharmacokinetics with dose

       proportional increases in exposures, and a half-life supporting

       once-daily administration.


-- Secondary endpoint: cognitive function (CogScreen(TM) test

   battery).


    -- Overall results on cognitive function showed a dose-dependent

       trend for improvement associated with PRX-07034.


    -- For the predetermined endpoint that combines speed and

       accuracy, there was a dose-dependent effect which was

       statistically significant (p=0.014 vs. placebo) at the 600 mg

       dose.


-- Additional findings: signals suggestive of pharmacologic activity

   were observed for obesity, even in the in-patient setting.


    -- A greater proportion of subjects on drug experienced weight

       loss during the o
'"/>




Page: 1 2 3 4 

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4
Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/5/2013)... Dec. 5, 2013  The Food and Drug Law ... professionals with its annual Distinguished Service and Leadership Award: ... Kay Holcombe and Richard Kingham . ... honorees will receive their awards at FDLI,s Holiday and ... Hotel in Washington, D.C. , which ...
(Date:12/5/2013)... MOUNTAIN VIEW, Calif. , Dec. 5, 2013 ... exhibiting at the American Society of Health-System ... Orlando . Omnicell,s 2013 theme, "How Far ... to support healthcare systems, patient management initiatives that ... environments. (Logo:  http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a ) ...
(Date:12/5/2013)... Dec. 5, 2013 With patients increasingly searching ... for prescription pharmaceuticals are ready for them. Just 28 ... Research,s new ePharma Competitive Analysis Series were ... it comes to mobile. They know it,s a critical ... enough," said Manhattan Research Vice President of Research ...
Breaking Medicine Technology:The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham 2The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham 3The Food and Drug Law Institute To Honor Axelrad, Gibbs, Holcombe, Kingham 4Omnicell Expands its Unity Platform to Further Integrate Workflows 2Omnicell Expands its Unity Platform to Further Integrate Workflows 3Omnicell Expands its Unity Platform to Further Integrate Workflows 4Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 2Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 3Few pharma websites optimized for mobile, according to Manhattan Research's new ePharma Competitive Analysis Series 4
... An analysis of medical-surgical sales through distribution ... 100 U.S. medical-surgical manufacturers by dollar spend, those that ... distribution by an average of 6.42 percent in 2009, ... of only 3.88 percent. Furthermore, GHX,s analysis also found ...
... July 29 In response to the agreement announced that CVS ... giant Aetna, the National Community Pharmacists Association (NCPA) issued the following statement from ... , PD: , , , ... , , , ...
Cached Medicine Technology:Analysis Finds U.S. Medical-Surgical Manufacturers Using GHX Market Intelligence Grew Revenue Faster Than Non-Users in 2009 2Analysis Finds U.S. Medical-Surgical Manufacturers Using GHX Market Intelligence Grew Revenue Faster Than Non-Users in 2009 3NCPA Statement on CVS Caremark-Aetna Agreement 2NCPA Statement on CVS Caremark-Aetna Agreement 3
(Date:12/5/2013)... WASHINGTON -- In most cases, human gene transfer research ... additional review from the National Institutes of Health,s Recombinant ... report by the Institute of Medicine. Patient safety ... RAC reviews no longer provide benefits beyond the existing ... advancement with unnecessary administrative burdens. , However, NIH ...
(Date:12/5/2013)... Every time someone signs their name at ... with a serious health hazard : chronic contamination ... what hazardous viruses, bacteria or diseases the person ahead ... throughout flu season in particular, do retail customers and ... to touch that?" (Of course not. But they have ...
(Date:12/5/2013)... Anglia are launching a new project to develop methods ... mice in pharmaceutical testing. , Researchers will use mammallian ... bid to create a new way of predicting drug ... reduce the need for animal testing in medical research., ... for the Replacement, Refinement and Reduction of Animals in ...
(Date:12/5/2013)... 05, 2013 Frantz EyeCare is pleased ... Florida who are still included on the United Healthcare ... Florida Blue, Aetna, Cigna and numerous other insurances. , ... Frantz , physicians’ relationships with insurance companies are becoming ... United Healthcare, which is one of the top healthcare ...
(Date:12/5/2013)... and animal studies have confirmed that acupuncture ... disease. Moxibustion is reported to be more ... ability in aged mice, suggesting that moxibustion ... to treat Alzheimer,s disease. Dr. Yanjun Du ... Medicine, China only used suspended moxibustion (also ...
Breaking Medicine News(10 mins):Health News:New IOM report assesses oversight of clinical gene transfer protocols 2Health News:New IOM report assesses oversight of clinical gene transfer protocols 3Health News:New Technology Automatically Sterilizes Dangerous Microbes at Point of Sale Terminals 2Health News:New Technology Automatically Sterilizes Dangerous Microbes at Point of Sale Terminals 3Health News:UEA researchers receive share of £1.26 million to reduce animal experimentation for drug development 2Health News:Frantz EyeCare Continues to Accept United Healthcare and Other Major Insurances 2
... Inc., a leading,global provider of enterprise Business Process ... solutions, announced,today that it will partner with DOKUMENTA ... Code (EPC Gen. 2) RFID solution, to help,suppliers ... Initiative. The Future Store Initiative is aimed ...
... The Governing Board,of Texas Medical Liability Trust ... for TMLT policyholders. The Board has,approved a 6.5% ... January 1, 2008. In addition, all current TMLT ... dividend equal to 22% of,their expiring premium. The ...
... Medical Services,International Inc. (Pink Sheets: MSITF) wishes to ... distributors indicate that it,will produce 1.24 million test kits ... of the fiscal year. The majority of the kits ... also deliver VScan TB,Malaria, Hepatitis C and Dengue Fever ...
... In Use of Anticonvulsants, Especially When Prescribed,Off-Label, ... in treating bipolar disorder, fibromyalgia, and various,kinds of ... always the best,initial choice to treat those conditions ... to the latest report from Consumer Reports Best ...
... Key Time to Start Talking With ,Tweens,: TimeToTalk.org, Provides Parents With Helpful ... ... -, NEW YORK, Sept. 5 ... drugs and alcohol, The Partnership for a,Drug-Free America(R),s new nationwide parent movement ...
... 2007 Inc. 5,000, No. 58 in the ... 97.2%, PORTLAND, Ore., Sept. 5 Inc. magazine has ... on,its first-ever Inc. 5,000 list of the fastest-growing private companies ... annual Inc.,500 list, catches many businesses that are too big ...
Cached Medicine News:Health News:Shipcom Partners With DOKUMENTA for METRO's Future Store Initiative 2Health News:Shipcom Partners With DOKUMENTA for METRO's Future Store Initiative 3Health News:Texas' Largest Physician Carrier Announces 5th Successive Rate Cut on Anniversary of Lawsuit Reform 2Health News:Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best 2Health News:Consumer Reports' Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best 3Health News:Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 2Health News:Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 3Health News:Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids 4Health News:First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion 2Health News:First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion 3Health News:First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: